Phase II and Phase III Clinical Trials in Progress

• CT206 Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Jordi Rodon, Michael Rothe, Elizabeth Garrett-Mayer, Nithin Rohatgi, Alvaro G. Menendez, Leighton A. Elliott, Andrew Gregory, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
• CT207 A prospective observational registry study on transplantation of liver outcomes in patients with a history of cancer within the past five years: Evaluating eligibility for liver transplantation Young Kwang Chae, Ronald Seungjune S. Min, Liam Il-Young Chung, Lane Herbert, Jacob Liskh, Sanghwa Kim, Donghoon Shin, Hangyul Lee, Christopher Moore, Sheila Eswaran, Dempsey Hughes, Justin Boike, Amanda Cheung, Daniel Ganger, James Crismale, Taehoon Lee, Laura M. Kulik, Sarang Thaker, Tarik Demir, Andres Duarte-Rojo
• CT208 Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound Arshit Narang, Prashant Prakash Lad, Shiladitya Sengupta
• CT209 DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
• CT210 Occupational cancer screening in firefighters: A pilot randomized study of whole-body screening modalities Bryan Bassig, Jennifer Lund, John F. Deeken, Salman Baig, Blair Allais, Rita Stanislawski, Megan Slocum, Elizabeth Hatcher, Jennifer Truax, Inger Rosner, Rebecca Kaltman
• CT211 Palbociclib (P) in patients (pts) with lung cancer (LC) with CCND1 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Evan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, Christopher M. Reynolds, Bamidele Adesunloye, Ramya Thota, Kathryn F. Mileham, Kelly Lynch, Rachel E. Sanborn, Timothy L. Cannon, Justin T. Moyers, Janet Tu, Mehmet Akce, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
• CT212 · PDF Neratinib efficacy in second line patients with EGFR exon 18-mutant non-small-cell lung cancer Steve Shen, Wenfeng Fang, Ning Li, Runxiang Yang, Ying Cheng, Baogang Liu, Haiyong Wang, Lin Wu, Qiming Wang
• CT213 A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET -fusion-positive NSCLC Jaime Rubio-Perez, Elena Garralda, Benjamin Besse, Mihaela Aldea, Yasir Elamin, Pilar Garrido, Saad Khan, Judy Wang, Luis Paz Ares, Daniel Morgensztern, Philippe Cassier, Salmon Punekar, Stephen V Liu, Matthew H Taylor, Liz Joseph, Andrew G Gianoukakis, Jacobi Hines, Javier Garcia-Corbacho, Pascale Tomasini, David Spigel, Matthew G Krebs, Antoine Italiano, Mohammad Al Masri, Geoff Fisher, Sonia Serrano, Hendrik-Tobias Arkenau, Alex Drilon
• CT214 DREAM: Double lung transplant REgistry Aimed for lung-limited Malignancies - A prospective registry study for medically refractory cancers Young Kwang Chae, Liam Il-Young Chung, Ronald Seungjune S. Min, Sanghwa Kim, Chan Mi Jung, Yuchan Kim, Brooke Sanson, Rose Dwyer, Tarik Demir, Chitaru Kurihara, Ambalavanan Arunachalam, Ankit Bharat
• CT215 · PDF RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
• CT216 OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS / BRAF wild-type colorectal cancer J. Randolph Hecht, Elena Élez, Cathy Eng, Peter Gibbs, Jenny Seligmann, Ruihua Xu, Kensei Yamaguchi, Jaw Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia Lorenzini, Christine Baudelet, Seema Sethi, Mahadi Baig, Chiara Cremolini
• CT217 OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS / BRAF wild-type metastatic colorectal cancer Dirk Arnold, Andres Cervantes, Michel Ducreux, Sae-won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Raghav, Lin Shen, Jaw Yuan Wang, Pei Jye Voon, Hung-Chuh Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia Lorenzini, Sandip Acharya, Seema Sethi, Mahadi Baig, Filippo Pietrantonio
• CT218 Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC) Sebastian Stintzing, Arndt Stahler, Annabel Alig, Isabel Löwstedt, Marcus Thuresson, Roger Tell
• CT219 A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial Michael B. Sawyer, Barry A. Badeau, Allison J. Gardner, Meghan Joly, William Riedl, LuAnn Sabounjian, Jillian L. Seiler, Brad Studnitzer, Emma Zhang, Russell Potterfield, Daniel L. Marks
• CT220 A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Interim efficacy subset analyses Daniel Flora, Ari Baron, Reema Patel, Davendra Sohal, Saima Sharif, Fa Chyi Lee, Julie Anne Gemmill, Gilles H. Tapolsky, James Beach, Michael Gazda, Tariq Arshad
• CT221 A progress report for a Phase 1b/2 study of ENPP1 inhibitor, vizenpistat in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer Alexis S. Larsen, Mohan R. Kaadige, Trason Thode, Margaux Steinbach, Scott Houston, Jonathan Northrup, Sunil Sharma
• CT222 Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial Marianne Pavel, Chris Verslype, Pedro Rocha, Alastair Greystoke, Aman Chauhan, Julia Koevi, Martha Mueller, Eric Song, Valeria Lifke, Andrea Standring, Emily Bergsland
• CT223 · PDF AACR Adaptive Biomarker-Driven Organ Preservation Trial in GE Adenocarcinomas (AACR-ADOPT-GEA) Elena Elimova, Jaffer Ajani, Samuel J. Klempner, Kurt Schalper, Zev Wainberg, Yuan Ying, Jan D. Baranski, Scott Boerner, Sienna M. Durbin, Denise Gallagher, Huh Won Jae, Ronan A. McLaughlin, Matthew R. Strickland, Eric H. Rubin, Lillian L. Siu, Timothy A. Yap, Patricia LoRusso
• CT224 Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (Teluride-006) Diwakar Davar, Bernardo Rapoport, Jan C. Simon, Oliver Bechter, Stephane Dalle, Yin Wu, Daniel Brungs, Anna Maria Di Giacomo, Hanna Eriksson, Peter Mohr, Rossanna Pezo, Egle Ramelyte, Gareth Rivalland, Toshifumi Hoki, Geetha Krishna Kaza, Yayan Zhang, Etah Kurland, Alexander Eggermont
• CT225 ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study Aditya Bardia, Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos H. Barcenas, William J. Gradishar, Michail Ignatiadis, David A. Cameron, Giulia Tonini, Simona Scartoni, Jennifer Crozier, Tomer Wasserman, Sara M. Tolaney
• CT226 ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with ESR1 -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i Antonio Llombart-Cussac, José Manuel Pérez-García, Elena Lopez-Miranda, Cristina Saavedra, Vicente Carañana, Isabel Blancas, Carmen Hinojo-González, Alfonso Cortes-Salgado, Elena Galve, Rui Rui Zhang, Miguel Sampayo-Cordero, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Ana Garrido, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Claire Hardy Bessard, Tomer Wasserman, Javier Cortés
• CT227 Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 Jaye Thompson, Snehal Patel, Mira Patel, Anu Tammareddi, F. Joseph Daugherty, Mothaffar F. Rimawi

在完整检索应用中浏览本分会场 →